Long-Acting Injectables in Schizophrenia Part 4: Enhancing Patient Outcomes

Consistent symptom control is essential not only for preventing relapse but also for supporting greater independence, social reintegration, and improved functional capacity in patient with schizophrenia. LAIs provide a stable, extended dose of medication, addressing common challenges with daily oral medication adherence. By reducing relapse risk and providing reliable symptom management, LAIs empower patients to engage more fully in personal goals, work, and relationships, enhancing their quality of life and promoting community involvement. Our advocate will share real-world experiences, illustrating how LAIs are helping patients lead more active, fulfilling lives. Whether you’re a patient, caregiver, or mental health professional, join us to learn how LAIs are positively impacting both individual and societal outcomes in schizophrenia care!
- - - -
Moderator: ​Christoph U. Correll, MD 
Faculty: Henry A. Nasrallah, MD
Patient Advocate: Bethany Yeiser, BS
- - - -
Earn free 0.50 AMA PRA Category 1 Credit™. Access for credit will be
shared at the end of this live event.
Click the link to view the Accreditation and Disclosure details before
participating: Medscape.org/viewarticle/1001964
Supported by an educational grant from Janssen Pharmaceuticals, Inc.,
administered by Janssen Scientific Affairs, LLC.